Back to Search Start Over

Paediatric aortic valve replacement using decellularized allografts.

Authors :
Horke, Alexander
Bobylev, Dmitry
Avsar, Murat
Meyns, Bart
Rega, Filip
Hazekamp, Mark
Huebler, Michael
Schmiady, Martin
Tzanavaros, Ioannis
Cesnjevar, Robert
Ciubotaru, Anatol
Laufer, Günther
Zimpfer, Daniel
Jashari, Ramadan
Boethig, Dietmar
Cebotari, Serghei
Beerbaum, Philipp
Tudorache, Igor
Haverich, Axel
Sarikouch, Samir
Source :
European Journal of Cardio-Thoracic Surgery. Oct2020, Vol. 58 Issue 4, p817-824. 8p.
Publication Year :
2020

Abstract

Open in new tab Download slide Open in new tab Download slide OBJECTIVES Options for paediatric aortic valve replacement (AVR) are limited if valve repair is not feasible. Results of paediatric Ross procedures are inferior to adult Ross results, and mechanical AVR imposes constant anticoagulation with the inherent risks. METHODS The study design was a prospective, multicentre follow-up of all paediatric patients receiving decellularized aortic homografts (DAHs) for AVR in 8 European centres. RESULTS A total of 106 children (77 boys) were operated (mean age 10.1 ± 4.8 years, DAH diameter 20.5 ± 3.8 mm). A total of 60 (57%) had undergone previous surgical interventions: 34 with 1, 15 with 2 and 11 with ≥3. There was one early death in a 12-year-old girl, who underwent her fourth aortic valve operation, due to intracerebral haemorrhage on extracorporeal membrane oxygenation after coronary reimplantation problems following 3-sinus reconstruction 1 year earlier. One 2-year-old patient died due to sepsis 2 months postoperatively with no evidence for endocarditis. In addition, a single pacemaker implantation was necessary and a 2.5-year-old girl underwent successful HTx due to chronic myocardial failure despite an intact DAH. After a mean follow-up of 3.30 ± 2.45 years, primary efficacy end points mean peak gradient (18.1 ± 20.9 mmHg) and regurgitation (mean 0.61 ± 0.63, grade 0–3) were very good. Freedom from death/explantation/endocarditis/bleeding/stroke at 5 years was 97.8 ± 1.6/85.0 ± 7.4/100/100/100% respectively. Calculated expected adverse events were lower for DAH compared to cryopreserved homograft patients (mean age 8.9 years), lower than in Ross patients (9.4 years) and in the same range as mechanical AVR (12.8 years). CONCLUSIONS Even though the overall number of paediatric DAH patients and the follow-up time span are still limited, our data suggest that DAHs may present a promising additional option for paediatric AVR. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
10107940
Volume :
58
Issue :
4
Database :
Academic Search Index
Journal :
European Journal of Cardio-Thoracic Surgery
Publication Type :
Academic Journal
Accession number :
146035346
Full Text :
https://doi.org/10.1093/ejcts/ezaa119